Time2Take on risk — making the link between insulin resistance and cardiovascular risk

Reaven GM Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1998;37:1595-607.

Virtanen KA , Lönnroth P. , Parkkola R. et al. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. JCEM2002;87:3902-10.

DeFronzo RA , Bonadonna RC , Ferrannini E. Pathogenesis of NIDDM. Diabetes Care1992; 15:318-68.

Iozzo P. , Chareonthaitawee P. , Dutka D. et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes2002;51:3020-4.

Williams IL , Wheatcroft SB , Shah AM et al. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes2002;26:754-64.

Zeng G. , Nystrom FH , Ravichandran LV et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to the production of nitric oxide in human ( vascular endothelial cells. Circulation2000;101: 1539-45.

Ferrannini E. , Natali A. , Capaldo B. et al. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension1997;30: 1144-9.

Centers for Disease Control and Prevention Mortality Databasehttp://www.wonder.cdc.gov (accessed 28/03/03).

Plutzky J. , Viberti G. , Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications2002; 16:401-15.

Lefkowitz RJ , Willerson JT Prospects for cardiovascular research . JAMA2001;285: 581-7.

Haffner SM , Lehto S. , Rönnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med1998;339:229-34.

Lotufo PA , Gaziano M. , Chae CU et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med2001;161:242-7.

Berenson GS , Srinivasan SR , Bao W. et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med1998;338: 1650-6.

Wheatcroft SB , Williams IL , Shah AM et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med2003;20:255-68.

Williams IL , Wheatcroft SB , Crossey PA et al. Visceral adiposity, obesity, weight loss and endothelial function in humansJ Physiol2003:547.P: Abs C127.

Ridker PM High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation2001;103:1813-18.

Lindsay RS , Funahashi T. , Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet2002;360: 57-8.

Dandona P. , Aljjada A. , Mohanty P. et al. Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?J Clin Endocrinol Metab2001;86: 3257-65.

Haffner S. , Greenberg AS , Weston WM et al. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation2002;106:679-84.

Raji A. , Seely EW , Bekins SA et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care2003; 6:172-8.

Bakris G. , Viberti G. , Weston WM et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes . J Hum Hypertens2003;17:7-12.

Bakris G. , Weston WM , Rappaport EB et al. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetesDiabetologia1999; 2(suppl 1):A230 and poster.

Bennett SMA , Jones NP , Agrawal A. et al. Rosiglitazone improves insulin sensitivity and 24-hour ambulatory blood pressure in subjects with IGTDiabetologia2001;44(suppl 1):A200, Abs 770.

Calvo C. , Lopez JE , Covelo M. et al. Diabetes and arteriosclerosis. The role of anatagonists of PPAR-gamma . Am J Hypertens2002;15:188A, Abs P-432.

Natali A. , Baldeweg E. , Toschi E. et al. Rosiglitazone directly improves endothelial function in type 2 diabetic patientsDiabetes2002;51(suppl 2): A142 and poster.

Toschi E. , Baldeweg S. , Gastaldelli A. et al. Direct vascular and metabolic effects of rosiglitazone. Diabetologia2002;45(suppl 1): Abs 844.